CRVS - Corvus Pharmaceuticals Inc Stock Price, Fair Value and News

$8.44+0.39 (+4.84%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CRVS Price Action

Last 7 days

-7.0%

Last 30 days

9.9%

Last 90 days

47.3%

Trailing 12 Months

1.9%

CRVS RSI Chart

CRVS Valuation

Market Cap

630.3M

Price/Earnings (Trailing)

-41.81

Price/Sales (Trailing)

261.54

EV/EBITDA

-54.32

Price/Free Cashflow

-19.56

CRVS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CRVS Fundamentals

CRVS Revenue

Revenue (TTM)

2.4M

Rev. Growth (Yr)

30.39%

Rev. Growth (Qtr)

15.49%

CRVS Earnings

Earnings (TTM)

-15.1M

Earnings Growth (Yr)

74.74%

Earnings Growth (Qtr)

-26.99%

CRVS Profitability

EBT Margin

-483.40%

Return on Equity

-21.01%

Return on Assets

-18.73%

Free Cashflow Yield

-5.11%

CRVS Investor Care

Shares Dilution (1Y)

16.22%

Diluted EPS (TTM)

-0.55

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.0M	2.2M	2.4M	0
2024	1.8M	2.3M	2.8M	1.8M
2023	564.0K	418.0K	271.0K	1.6M
2022	339.8K	444.5K	549.3K	654.0K
2021	0	0	0	235.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CEO	Dr. Richard A. Miller M.D.
WEBSITE	corvuspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	29

Corvus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Corvus Pharmaceuticals Inc? What does CRVS stand for in stocks?

CRVS is the stock ticker symbol of Corvus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corvus Pharmaceuticals Inc (CRVS)?

As of Wed Dec 03 2025, market cap of Corvus Pharmaceuticals Inc is 630.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRVS stock?

You can check CRVS's fair value in chart for subscribers.

Is Corvus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRVS is over valued or under valued. Whether Corvus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Corvus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRVS.

What is Corvus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CRVS's PE ratio (Price to Earnings) is -41.81 and Price to Sales (PS) ratio is 261.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRVS PE ratio will change depending on the future growth rate expectations of investors.